Ascletis Pharma has returned for an $80m round that will fund the further clinical development of a potential treatment for non-alcoholic steatohepatitis symptoms.
Author: Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Reach Capital grabs $165m
The edtech-focused firm has raised $165m from limited partners including Sesame Workshop, Kaiser Foundation Hospitals and National Geographic Society.
And as the morning steals upon the night, melting the darkness
To say that 2020 was an annus horribilis would be an understatement.
Decibel resonates with public markets
The hearing loss treatment developer has raised more than $127m in its initial public offering that offered exits to Alphabet, GlaxoSmithKline and Regeneron.
Coupang books $1bn IPO ticket
Coupang is reportedly looking to achieve a $50bn market cap following a planned listing that would offer an exit to both SoftBank and its Vision Fund.
NexImmune collects IPO proceeds
NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.
Ensoma emerges with $70m series A
Takeda Ventures and Alexandria Venture Investments have taken part in a $70m series A round for Ensoma, with Takeda separately signing a strategic collaboration deal.
Immunai initiates $60m series A
Dexcel Pharma has co-led a $60m series A round for Immunai, which previously collected $20m in seed financing less than a year ago.
Swift Navigation accelerates with $50m series C
KDDI Open Innovation Fund has thrown its weight behind Swift Navigation, a global positioning technology developer already backed by Qualcomm Ventures.
IWG takes up residence in The Wing
IWG has acquired a majority stake in the co-working space provider just weeks after GV bought the shares held by WeWork.
Notch marks $85m series A round
Existing strategic investor Allogene Therapeutics has taken part in an $85m series A round for Notch Therapeutics, which is working on cancer treatments.
SpyBiotech detects GV for series A round
GV returned for SpyBiotech’s $32.5m series A round, as it looks to move its first potential vaccine into the clinic by early next year.
IST Cube squares $48m fund
Vienna Insurance is among the limited partners for a $48m seed-stage fund aimed at university spinouts in Austria.
Immunocore makes $258m impact in IPO
Eli Lilly and WuXi AppTec scored exits from the immunotherapy developer, which has seen its shares rocket 66% since it floated.